Phase 2 N=56 Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma
Metastatic Osteosarcoma · Recurrent Osteosarcoma · Refractory Osteosarcoma
Primary: Disease Control Rate (Cohort I) — 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=19 Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma
Recurrent Osteosarcoma
Primary: Disease Control Success — 0 participants
Phase 2 N=22 Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma
Recurrent Osteosarcoma
Primary: Disease Control Success — 3 Participants
Phase 2 N=49 Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma
Metastatic Cancer · Sarcoma
Primary: Status of FAS Ligand in Pre-chemotherapy Sample — 7; 5; 1; 1 participants
Phase 2 N=54 Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma
Sarcoma
Primary: Objective Response Rate — 6; 5; 14 participants
Phase 2 N=41 Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
Metastatic Malignant Neoplasm in the Lung · Metastatic Osteosarcoma · Recurrent Osteosarcoma
Primary: Disease Control — 11 Participants
Phase 3 N=1,334 Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma
Localized Osteosarcoma · Metastatic Osteosarcoma
Primary: Event-free Survival (EFS) — 74; 77; 55; 53 Percentage EFS — p=0.214
N/A N=545 Patterns of Care and Outcomes in Patients With Metastatic Bone Tumors (METABONE)
Metastatic Bone Tumor
Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months
Phase 2 N=18 A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma
Osteosarcoma
Primary: Response Rate — 0 percentage of participants
Phase 2 N=59 Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma
Osteosarcoma · Ewing Sarcoma · Rhabdomyosarcoma
Primary: Response Rate — 15.3 percentage of participants
Phase 2 N=11 Samarium Sm 153 and Stem Cell Transplant Followed By Radiation Therapy Patients With Osteosarcoma
Sarcoma
Primary: Tumor Response — 10 participants
Phase 2 N=43 A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma
Osteosarcoma · Malignant Fibrous Histiocytoma (MFH) of Bone
Primary: Number of Participants With Unacceptable Toxicity — 0; 0; 0; 0 participants
Phase 2 N=12 Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma
Ewing's Sarcoma
Primary: Objective Response Rate of Olaparib — 0 Participants
Phase 2 N=32 Chemotherapy for Patients With Osteosarcoma
Osteosarcoma
Primary: Percentage of Participants With Tumor Response — 3.1; 0; 3.1; 15.6 percentage of participants
Phase 2 N=60 Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas
Sarcoma
Primary: Number of Participants With Engraftment — 23 Participants
Phase 2 N=72 A Study of Pemetrexed in Children With Recurrent Cancer
Osteosarcoma · Medulloblastoma · Sarcoma, Ewing's
Primary: Percentage of Participants With Overall Tumor Response (Response Rate) — 0; 0; 0; 0 Percentage of Participants
N/A N=2,165 Patterns of Care and Outcomes in METAstatic Soft Tissue SARComa
Sarcoma · Metastases · Chemotherapy
Primary: Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment — 0.76 correlation coefficient
Phase 2 N=19 Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung
Osteosarcoma Metastatic
Primary: The Study Medication Was to be Considered Effective if the Population Response Rate Was Found to be Greater Than 20% and Individuals Who Demonstrated a CR or PR or Whose…
Phase 3 N=588 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Adult Alveolar Soft-part Sarcoma · Adult Angiosarcoma · Adult Epithelioid Sarcoma
Primary: Probability for Event Free Survival. — 0.8984; 0.7647; 0.6079; 0.4873 Probability of EFS at 5 years
Phase 2 N=81 A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma
Osteosarcoma
Primary: Progression-free Survival (PFS) by Independent Imaging Review (IIR) Assessment — 6.5; 5.5 months — p=0.0396
Phase 2 N=10 Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma
Sarcoma
Primary: Response — 10; 0 participants
Phase 2 N=40 Phase II Study of Chemotherapy and Pamidronate for the Treatment of Newly Diagnosed Osteosarcoma
Osteosarcoma
Primary: Radiographic Response — 21; 5; 5; 3 participants
Phase 2 N=136 Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
Sarcoma
Primary: Progression Free Survival — 186; 271 Days
Phase 1 N=23 Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma
Solid Tumor · Osteosarcoma
Primary: Dose Escalation Part: Number of Dose-Limiting Toxicities (DLTs) at Each Dose Level on Cycle 1 — 0; 2 Number of DLTs
Phase 2 N=52 Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer
Borderline Ovarian Serous Tumor · Low Grade Ovarian Serous Adenocarcinoma · Micropapillary Serous Carcinoma
Primary: Tumor Response — 15.4 percentage of patients
Phase 1 N=24 Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma
Sarcoma
Primary: Limiting Toxicity — 1; 1; 3; 2 participants
Phase 2 N=15 Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
Cancer of the Pharynx · Cancer of the Larynx · Cancer of the Neck
Primary: Toxicity — 0; 1; 2 participants
Phase 2 N=147 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
Adult Angiosarcoma · Adult Epithelioid Sarcoma · Adult Leiomyosarcoma
Primary: Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST — 1; 0; 0; 0 participants
N/A N=7 Surgery With or Without Adjuvant Stereotactic Body Radiotherapy
Head and Neck Cancer
Primary: 1-year Local Control — NA; NA months
N/A N=9 (SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas
Stage IV Adult Soft Tissue Sarcoma · Sarcoma,Soft Tissue
Primary: Number of Adverse Events of Grade ≥ 3 by CTCAE Criteria. — 8 events